Hangzhou, China — May 12, 2026, 17:05 (China Standard Time)
- WORK Medical Technology Group LTD said it’s teaming up with Novabioplus to focus on AI-powered protein and biological data modeling.
- WOK surged 206.25% to finish Monday at $3.92, having bounced from $0.19 to $4.09 during the session.
- The small Nasdaq-listed medical-device supplier is making the shift as it looks to reposition itself in AI, Web3, and healthcare data.
Shares of WORK Medical Technology Group LTD swung sharply in Tuesday’s premarket, after the U.S.-listed stock soared more than threefold on Monday. The move tracked news of an AI tie-up with Shanghai Novabioplus Biotechnology Co. The two firms aim to create medical models leveraging protein data and what WORK calls “BioTokens”—digital assets representing biological data. GlobeNewswire
It’s all about when the moves happened. WOK finished Monday at $3.92, a 206.25% surge from Friday’s close, after swinging between $0.19 and $4.09 during the session. Early Tuesday premarket, StockAnalysis had the shares at $2.05—off 47.7% from that Monday finish.
It’s a key point: WORK is still a small name, looking to diversify out of medical consumables. Reuters, citing LSEG data, reports 2025 revenue at $9.85 million, with the company running a net loss of $1.07 million. Shuang Wu is in charge as both chairman and chief executive.
WORK announced it inked a deal with Novabioplus on April 13, targeting four “AI+” initiatives: membrane protein design, antibody sequence optimization, enzyme molecule design, and peptide design. Essentially, both firms aim to leverage software models along with lab data to design biological molecules for drug research. Investing.com India
The statement stopped short of outlining revenue goals, naming customers, or disclosing deal terms. Instead, it mentioned possible joint investments and a mix of industrial resources with capital, but the vague language leaves both timing and any financial upside up in the air.
WORK is heading into a space packed with well-backed players. Back in January, Reuters noted that Certara, Schrödinger, and Recursion Pharmaceuticals were already relying on AI to predict how drugs are absorbed, distributed, and what toxicities might crop up. Big pharma, too, has been digging further into AI-powered datasets for drug discovery.
Deal activity has picked up in this area. Back in March, Reuters noted Eli Lilly broadened its AI drug-discovery collaboration with Insilico Medicine, a move that could be worth as much as $2.75 billion. Insilico’s founder and CEO, Alex Zhavoronkov, pointed to AI’s potential for spotting “multi-purpose targets driving multiple diseases at the same time.” Reuters
WORK’s latest move with Novabioplus comes after its May 1 disclosure: the company co-wrote an asset-tokenization whitepaper and began pushing into healthcare real-world assets, AI payments, and stablecoin-based cross-border settlement. Real-world assets, or RWAs, are physical or data assets put into digital form—typically on blockchains.
The core operation is straightforward. According to Reuters’ company profile, WORK focuses on producing medical devices—think medical face masks, endotracheal tubes, breathing circuits, laryngeal mask airways, oxygen masks, and various other Class I and Class II disposables. Sales reach China as well as markets in Asia, Africa, Europe, and North America.
There’s a risk here: the market seems to be betting on a strategy without hard evidence. In a December SEC filing, WORK disclosed a one-for-100 reverse split—an attempt to satisfy Nasdaq’s minimum bid-price requirement and avoid delisting. That same filing listed roughly 1.22 million ordinary shares outstanding following the move.
So far, investors have seen a swift move in the stock, a cooperation agreement inked, and a fresh AI-data pitch. Still missing: any word on when a product will actually launch, concrete financial commitments, or proof that BioTokens could turn into a meaningful business for WORK.
